Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

This program funds preclinical development of therapeutic agents for neurological or neuromuscular disorders, including characterization, pharmacokinetic studies, pharmacodynamic studies, and in vivo efficacy studies. It supports small molecules and biologics such as peptides, proteins, oligonucleotides, gene therapies, and cell therapies, but not optimization, IND-enabling work, clinical studies, or basic disease mechanism research. Eligible applicants include U.S. and non-U.S. organizations, including nonprofits, universities, governments, for-profits, and small businesses, and foreign organizations and foreign components are allowed. Direct costs cannot exceed $499,000 in any one year and $750,000 over the full three-year project period, with no more than two years in either the R61 or R33 phase. No cost sharing is required, and clinical trials are not allowed.

✳ AI-generated summary — verify against the announcement

• Health
• Research & Discovery
• Technology & Product Development
• Patients & People with Health Conditions
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments